

Galectin Therapeutics Inc. Investor Relations Department 4960 Peachtree Industrial Boulevard, Suite 240 Norcross, GA 30071 United States

Visit IR website ☐ Sign-up for email alerts ☐

NASDAQ: GALT	
Last Trade:	2.18
Trade Time:	4:00 PM ET Jul 21, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.49 - 3.68
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Corporate Profile

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in... (more)

Stock Performance



Press Releases [View all]

Jul 7, 2017

<u>Galectin Therapeutics to Present at the</u> <u>Singular Research Summer Conference</u>

Jun 21, 2017

Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics

Jun 13, 2017

Galectin Therapeutics Announces Important
Milestones towards Completion of NASH CX
Trial

Financials [View all]

First Quarter Financial Results

Mar 28, 2017

Annual Report (10-K)

Nov 10, 2016

Proxy Statement (DEF 14A)

May 15, 2017

Quarterly Report (10-Q)

Nov 8, 2016

Quarterly Report (10-Q)

Aug 9, 2016

Quarterly Report (10-Q)